Mobic (Meloxicam) for Sciatica Pain
Yes, Mobic (meloxicam) can help relieve sciatica pain, with evidence showing it is more effective than placebo and as effective as other NSAIDs like diclofenac for short-term pain relief. However, the evidence for radicular low back pain (sciatica) is limited, and benefits are typically small to moderate and short-term (generally <3 months) 1.
Evidence Quality and Strength
The most recent high-quality guideline from 2017 1 provides the framework: NSAIDs show small benefits (5-10 points on a 100-point pain scale) for chronic low back pain with moderate strength of evidence, but evidence specifically for radiculopathy (sciatica) is very limited. The older 2007 guideline 2 found "good evidence" that NSAIDs are effective for short-term pain relief in general low back pain, but could not draw definite conclusions about sciatica specifically due to few trials.
Clinical Trial Data for Sciatica
Research studies specifically examining meloxicam for sciatica show:
Two randomized controlled trials 3 with 1,021 patients demonstrated that meloxicam 7.5 mg and 15 mg significantly improved overall pain compared to placebo (p<0.05) and were as effective as diclofenac 150 mg in acute sciatica over 7-14 days.
A smaller trial 4 of 113 patients showed both intramuscular and oral meloxicam 15 mg significantly improved pain at 30-60 minutes in acute sciatica.
Observational data 5 from 2,078 patients with acute back pain (including sciatica) showed 75% achieved complete pain relief with meloxicam 15 mg/day, though patients with sciatica had poorer outcomes requiring "special control and integrated treatment."
Practical Recommendations
Start with meloxicam 15 mg once daily for acute sciatica pain. The FDA label 6 confirms this is the maximum recommended dose, as higher doses (22.5 mg and greater) increase serious GI event risk without additional benefit.
Expected Outcomes:
- Pain reduction of 5-10 points on a 0-100 scale (small benefit)
- Effects typically seen within 30-60 minutes to days
- Duration of benefit generally <3 months
- Functional improvement is less consistent than pain relief 1
Important Caveats:
Cardiovascular and GI risks: The FDA label 6 warns that NSAIDs increase risk of serious cardiovascular thrombotic events, MI, and stroke, as well as GI bleeding, ulceration, and perforation. These risks increase with longer use, higher doses, and in patients with cardiovascular disease or GI risk factors.
Limited evidence for radiculopathy: The 2017 guideline 1 explicitly notes that "evidence on pharmacologic therapies for radiculopathy was very limited." This means while meloxicam likely helps based on NSAID class effects and specific sciatica trials, the evidence base is weaker than for non-radicular back pain.
Sciatica predicts poorer response: Observational data 5 shows that sciatica, severe baseline pain (≥7/10), and pain at rest/night are associated with poorer treatment outcomes with NSAIDs alone.
When Meloxicam May Not Be Sufficient
If pain remains >3/10 after 7-14 days of meloxicam, consider:
- The evidence does not support adding muscle relaxants or B vitamins to NSAIDs 5
- Gabapentin has "fair evidence" for radiculopathy specifically 2
- Periradicular injection of meloxicam (10-20 mg) shows promise in research studies 7, 8, 9 for refractory cases, though this is not standard practice
Use the lowest effective dose for the shortest duration necessary 6, typically not exceeding 2-3 months based on the evidence showing short-term benefits 1.